BitMine Immersion Technologies purchased 27,562 Ethereum tokens for $75 million, bringing its total holdings to nearly 6 million ETH, or about 4.9% of the circulating supply. Valued at $16.1 billion, BitMine is the largest corporate holder of Ethereum and is close to its goal of owning 5% of all ETH. The company stakes about 85% of its Ethereum, generating significant annual revenue, and expects increased institutional investment in crypto as US regulations evolve.
BitMine's Ethereum holdings total nearly 6 million ETH, representing about 4.9% of the circulating supply and valued at $16.1 billion. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 21, 2026 19:56 WIB: out of 50 major cryptocurrencies priced on Pluang, 47 rose and 2 fell today. Notable movers include DOGE with a 10.44% increase and a typical hold time of 109 days, BCH up 10.16% with a 68-day hold time, and SUSHI rising 10.09% with a 101-day hold time.
Admiral Group Plc announced that as of October 30, 2026, its total issued share capital consists of 305,254,676 ordinary shares, each with one voting right, totaling the same number of voting rights. There are no treasury shares held by the company. ...
Juniper Research forecasts the global Communications Platform as a Service (CPaaS) market will more than double from $21 billion in 2026 to over $50 billion by 2031. Growth is driven by rising use of conversational AI, authentication, and new messagi...
PayPoint Plc announced that as of October 30, 2026, the company has 58,266,801 ordinary shares outstanding, each carrying one vote at general meetings. The company holds no shares in treasury. This figure is important for shareholders and regulators ...
Geely Auto Group reported October vehicle sales of 310,183 units, surpassing 300,000 for the first time in 2026, marking eight consecutive months of year-over-year and month-over-month growth. New energy vehicles (NEVs) accounted for 69% of sales, re...
Oculis Holding AG has appointed Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to lead the global scientific strategy for advancing its neuroprotective drug candidate Privosegtor. Privosegtor, aimed at treating optic neuritis and other ne...
